Relax RD. Once the first cash dividend is paid out in a couple of months it will immediately legitimize the company and their commitment to shareholder value. The average investor can't visit operations/talk to management directly to do their due diligence so the majority look at the price to determine whether a company is a fraud or not. We are all too familiar with the unfortunate events that brought the price down..but things have finally started to turn around.
After the ex-dividend is announced and paid, new investors who have never even heard of SIAF yet, will look at a stock that finally has a rising stock price, still has a high cash dividend yield even at $1 and is still very undervalued relative to all metrics P/B, PE, etc. Valuation doesn't matter when people think it's a fraud. Period. As soon as you legitimize the company, which they will in a matter of months, people will seriously look at the company including institutional investors who I expect to step up once the ex-date is announced shortly.
This is a company that is profitable, returning to growth, distributing preferred shares which dividends can be paid through, and cash dividends. On top of that is of course additional contracts/financing finally closing to increase the growth rate.
I don't know what your 2018/19 EPS estimates are but do you think such a company should command at least a 10 PE ratio, and if so what price would that put it at? Incredibly asymmetric risk/reward scenario here. I see no better investment with such an enormous upside. And the enormous upside is not dependent on creating a cure for cancer, but simply by following through on the plan they have already laid out which is being guided by Garrett who is incredibly incentivized to see it followed through accordingly. The information in the Q2 report provided updates and very strong indications that the plan is indeed being followed through.
